Based on our functional and mechanistic findings NMI and DRAM1 play key roles in determining the response of breast cancer to cisplatin and we suggest that NMI and DRAM1 levels may offer additional parameters towards these patient considerations. The gene discussed is DRAM1; the disease is breast carcinoma.